Genetic Technology News

摘要

Genes Linked to Lymphoma; Epivax Tularemia Vaccine; Lexicon Focus Is Changing; GTN Strategic Partners; Some Important Patents for You To Check; A combination of interferon alpha and ribavirn, a synthetic antiviral compound, is the current standard ofcare for chronic hepatitis virus C (HCV) infection. ZymoGenetics Inc. has started a phase I clinical trial of polyethylene glycol (PEG)-interferon lambda (interleukin-29; IL-29) as a potential replacement in this therapy for interferon-alpha, which can have significant side effects. The phase I safety and pharmacokinetic study of PEG-interferon lambda will be carried out with healthy volunteers.